Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)

Phase 2 Completed 182 enrolled Fudan University

NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, open-lable Phase II clinical trial (ORCHID study) evaluating the effectiveness and safety of oral vinorelbine or capecitabine combined with trastuzumab as adjuvant treatment for patients with lymph node negative, HER-2 positive and small tumor size breast cancer

Timeline

Start: 2020-03-10
Primary completion: 2026-04-25
Completion: 2026-04-25

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Capecitabine	Small molecule	—	Oral
Subject	Trastuzumab	Monoclonal antibody	—	—
Subject	Vinorelbine	Small molecule	—	Oral

Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)

Summary

Timeline

Drugs

Indications